



**Government of the District of Columbia
Department of Health**



**899 NORTH CAPITOL ST. NE – 2ND FLR.
WASHINGTON, DC 20002**

October 7 2016

9:30am- 11:30 am

OPEN SESSION AGENDA

Board of Pharmacy Mission Statement:

“To protect and improve the public health through the efficient and effective regulation of the practice of Pharmacy and Pharmaceutical Detailing; through the licensure of Pharmacists, Pharmaceutical Detailers, Pharmacy Interns, and Pharmacy Technicians.”

Open Session Agenda

Quorum: Yes

Introduction:		
1007-O-01	<u>Approval of the Open Session Meeting Minutes</u> August 4, 2016	
<u>Consent Agenda</u>	None	
<u>Executive Director Report</u>	<u>Licensing Report</u> Statistics PMP Update Pharmacy Technician Update	
<u>Assistant General Counsel Report</u>		
	None	
<u>Legislative and Regulatory Subcommittee Report</u>		
1007-O-03	Collaborative Practice Agreement Regulations	Mr. Alan Friedman
1007-O-04	Communications Subcommittee Report	Dr. Daphne Bernard
NABP E-Newsletter	September 28, 2016 Virtus Pharmaceuticals Opco II, LLC, Recalls Batches of Hyoscyamine Sulfate Due to Superpotent and Subpotent Results Redesigned NABP Website to Launch Tomorrow FDA Announces Meeting on Implementing DSCSA's Product Identification Requirements Rogue Websites Selling Drugs Illegally Pose Health Threat; .Pharmacy Provides Safe and Legal Medicines NABP and CriticalPoint Announce First Class of Inspectors Who Earned Certification in Sterile Compounding	

	<p>NABP Seeks Pharmacists From Districts 1, 5, and 7 to Serve as Volunteer Item Writers</p> <p>September 21, 2016</p> <p>FDA Responds to Action Items From Intergovernmental Working Meeting on Pharmacy Compounding</p> <p>SAMHSA Report Finds 19 Million People Misused Prescription Psychotherapeutic Drugs in 2015</p> <p>Novo Nordisk, Inc, Voluntarily Recalls Six Batches of GlucaGen HypoKit Due to Detached Needles</p> <p>New FDA Webinar Provides Students and Health Care Providers With Information on Prescription Drug Promotion</p>	
<u>Matters for Board Consideration</u>	None	
<u>Comments from the Public</u>	Presentation: Teenage Prescription Drug Abuse and how it affects DC Dr. Adeoye Owolewa, Pharm.D. RPh	
1007-O-05	<p>The Board will conduct a disciplinary hearing in the matter of Patricia O'Malley, R.Ph., at 11:00 a.m. In accordance with 17 DCMR § 4109.1, the hearing is open to the public.</p> <p>(a) Notice of Summary Action to Suspend License</p>	
Motion to Adjourn the Open Session	Madam Chair, I move that the Board close the Open Public session portion of the meeting and move into the Closed Executive Session portion of the meeting pursuant to D.C. Official Code § 2-575(b) for the following purposes: to discuss disciplinary matters pursuant to § 2-575(b)(9); to seek the advice of counsel to the board, to preserve the attorney-client privilege, or to approve settlement agreements pursuant to § 2-575(b)(4);	

This concludes the Public Open Session of the meeting. The Board will now move into the Closed Executive Session portion of the meeting pursuant to D.C. Official Code § 2-575(b) for the reasons set forth in the motion.

Open Session Meeting Adjourned at ___: ___